Is TB-500 safe for dogs?
The short answer
TB-500 is generally well tolerated in the veterinary literature, with injection-site swelling the most common observation. The decisive safety question is not tolerance but cancer status: because the compound is associated with promoting new blood vessel growth and cell migration, it is contraindicated in dogs with active or suspected malignancy. Screening before starting is not optional. It is also banned in competitive racing and is detectable on testing.
The critical risks
⚠ Contraindicated with active cancer
TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
Additional cautions
Banned in competitive racing
TB-500 is a prohibited substance in racing and is detectable in urine and plasma. Do not administer to any dog competing under an anti-doping authority.
What the evidence base actually is
Safety claims are only as good as the studies behind them.
TB-500 is a synthetic fragment of thymosin beta-4, a protein found naturally throughout the body and concentrated at wound sites. The active portion binds actin, the structural protein cells use to move. Research describes this helping repair cells migrate into damaged tissue, alongside new blood vessel formation and collagen laydown.
Dosing context
Safety is dose-dependent. These are the figures reported in the source literature.
| Weight class | Reported dose | Frequency | Duration | Studied for |
|---|---|---|---|---|
| Small / toy breedunder 22 lb (10 kg) | 1-2.5 mg per week | Loading 1-2x weekly, then half dose weekly | Loading 2-4 weeks, maintenance 4-8 weeks | Soft tissue injury, wound healing |
| Medium breed22–77 lb (10–35 kg) | 2-5 mg per week | Loading 1-2x weekly, then half dose weekly | Loading 2-4 weeks, maintenance 4-8 weeks | Tendon and ligament injury, mobility, post-surgical recovery |
| Large / giant breedover 77 lb (35 kg) | 5-12 mg per week | Loading 1-2x weekly, then half dose weekly | Loading 2-4 weeks, maintenance 4-8 weeks | Orthopaedic injury, chronic joint disease |
See the full TB-500 profile for mechanism, protocol and monitoring detail.
Common questions
Is TB-500 safe for dogs?+
TB-500 is generally well tolerated in the veterinary literature, with injection-site swelling the most common observation. The decisive safety question is not tolerance but cancer status: because the compound is associated with promoting new blood vessel growth and cell migration, it is contraindicated in dogs with active or suspected malignancy. Screening before starting is not optional. It is also banned in competitive racing and is detectable on testing.
What are the side effects of TB-500 in dogs?+
Contraindicated with active cancer: TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered. Banned in competitive racing: TB-500 is a prohibited substance in racing and is detectable in urine and plasma. Do not administer to any dog competing under an anti-doping authority.
Can TB-500 be given to a dog with cancer?+
No. TB-500 is contraindicated in dogs with active or suspected cancer. TB-500 is associated with promoting angiogenesis and cell migration in preclinical models — the same two processes tumours depend on to grow and spread. Any dog with a known or suspected malignancy should be screened and cleared before this compound is considered.
Does my dog need testing before starting TB-500?+
No compound-specific genetic testing is established for TB-500. Baseline bloodwork before starting, and repeat testing during a protocol, is standard practice and lets your veterinarian catch a problem before it becomes clinically apparent.
References
- 1.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 2.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 3.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 4.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
- 5.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.